Prof. Ethier was originally trained as a mechanical engineer, receiving his Ph.D. from MIT in 1986 working in the lab of Roger D. Kamm. He then joined the University of Toronto, where he was a Professor of Bioengineering, Mechanical Engineering and Ophthalmology, and latterly the Director of the Institute of Biomaterials and Biomedical Engineering. Prior to joining Georgia Tech/Emory, Professor Ethier was the Head of the Department of Bioengineering at Imperial College, London from 2007-12. 

His research is in the biomechanics of cells and whole organs. His specific research topics include glaucoma (biomechanics of aqueous humour drainage in the normal and glaucomatous eye, and the mechanical and cellular response of optic nerve tissues to intraocular pressure), study of hemodynamic basis of arterial disease.

Dr. Susan S. Margulies leads the U.S. National Science Foundation’s Directorate for Engineering in its mission to transform our world for a better tomorrow by driving discovery, inspiring innovation, enriching education, and accelerating access. With an annual budget of nearly $800 million, the NSF’s Engineering Directorate provides over 40 percent of federal funding for fundamental research in engineering at academic institutions, and it distributes more than 1500 awards supporting research and education each year. Projects funded by the Engineering Directorate span frontier research to generate new knowledge, problem-driven research to identify new solutions to societal challenges, and application-driven research to translate discoveries to uses that benefit society.

In partnership with industry and communities across the nation, the NSF’s investments in engineering research and education lead to innovative technologies and sustainable impacts in health, agriculture, clean energy and water, resilient infrastructure, advanced manufacturing and communication systems, and many other areas. NSF support also builds the Nation’s workforce capacity in engineering and supports the diversity and inclusion of engineers at all career stages. Together, the NSF’s investments in engineering research and education enhance prosperity, equity and quality of life for all Americans.

Margulies joined the NSF as the assistant director for the Directorate for Engineering in August 2021 after leading the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University. While on detail at the NSF, she is a professor and Georgia Research Alliance Eminent Scholar at Georgia Tech and Emory. She received her B.S.E. in mechanical and aerospace engineering at Princeton University, her Ph.D. in bioengineering from the University of Pennsylvania, and post-doctoral training at the Mayo Clinic. She joined the faculty at the University of Pennsylvania in 1993 as an assistant professor, rising through the ranks to professor. In 2017 she became the first faculty member tenured in both the Georgia Institute of Technology and Emory University, and she was a department chair in both the college of engineering at Georgia Tech and Emory’s school of medicine. 

Margulies is internationally recognized for pioneering studies spanning the micro-to-macro scales and across species to identify mechanisms underlying brain injuries in children and adolescents and lung injuries associated with mechanical ventilation, leading to improved injury prevention, diagnosis and treatments. She has launched numerous training and mentorship programs for students and faculty, created institute-wide initiatives to enhance diversity and inclusion, and led innovative projects in engineering education. 

Margulies’ transdisciplinary scholarly impact has been recognized by her election as fellow of the American Society of Mechanical Engineers, the Biomedical Engineering Society, and the American Institute for Medical and Biological Engineering, and as a member of the National Academy of Engineering and the National Academy of Medicine.  

Dr. Hanjoong Jo is John and Jan Portman Professor in the Coulter Department of Biomedical Engineering (BME) at Georgia Tech and Emory University, and Professor of Medicine at Emory University. He is also the Associate Chair of Emory in BME Department. Upon graduation from Korea University, Dr. Jo received PhD under the co-mentorship of Professors John Tarbell (Chemical Engineering) and Ted Hollis (Physiology) at Pennsylvania State University in 1989. Following postdoctoral training in Jay McDonald Lab at Washington University in St. Louis and University of Alabama at Birmingham, he became Assistant Professor in Pathology and BME. Dr. Jo joined the BME Department at Georgia Tech and Emory University in 2000. He directs the Cardiovascular Mechanobiology and Nanomedicine lab. His lab studies how mechanical force associated with blood flow regulates vascular biology and cardiovascular disease, especially atherosclerosis, aortic valve (AV) calcification, and abdominal aortic aneurysms. He has published more than 150 peer-reviewed papers and edited two books. He developed the mouse model of atherosclerosis, known as partial carotid ligation model, induced by disturbed flow. His work led to the discovery of several genes (mechanosensitive genes and microRNAs) and epigenetic controlling mechanisms that are regulated by bad blood flow and play key roles in atherosclerosis and AAA. By targeting some of these mechanosensitive genes, his lab has been able to treat atherosclerosis and AAA in mice. His lab is now working on nanotechnologies to developing targeted gene and drug therapies in an effort to translate mouse studies toward clinical application. He is an elected fellow of American Institute of Medical and Biological Engineering, Biomedical Engineering Society, American Heart Association and American Physiological Society. He serves as associate editors and editorial board members of several cardiovascular and biomedical engineering journals including Scientific Reports, Circulation Research, Atherosclerosis Thrombosis Vascular Biology, Am J Physiology, Cell Molecular Bioengineering and Cardiovascular Engineering and Technology. He also has been serving as reviewers and chairs of study sections of the NIH, NSF, Veterans Administration and Am Heart Association. He also organized several international meetings, and in 2012, he served as the Chair of the Annual BME Society Meeting. He is also the founding President of Korean-American BME Society and Chairs of US-Korea Annual BMES Workshops since 2013. He has been a Distinguished Visiting Professor at Ewha Womans University and Chonbuk National University.

James Dahlman is a bioengineer / molecular engineer whose work lies at the interface of chemistry, nanotechnology, genomics, and gene editing. His lab focuses on targeted drug delivery, in vivo gene editing, Cas9 therapies, siRNA therapies, and developing new technologies to improve biomaterial design. 

The DahlmanLab is known for applying 'big data' technologies to nanomedicine. The lab is pioneering DNA barcoded nanoparticles; using DNA barcodes, >200 nanoparticles can be analyzed simultaneously in vivo. These nanoparticles are studied directly in vivo, and used to deliver targeted therapies like siRNA, mRNA, or Cas9. As a result of this work, James was named 1 of the 35 most innovative people under the age of 35 by MIT Technnology Review in 2018. James has won many national / international awards, and has published in Science, Nature Nanotechnology, Nature Biotechnology, Nature Cell Biology, Cell, Science Translational Medicine, PNAS, JACS, ACS Nano, Nano Letters, and other journals. James has also designed nanoparticles that efficiently deliver RNAs to the lung and heart. These nanoparticles can deliver 5 siRNAs at once in vivo, and are under consideration for clinical development. As a result, the lab has an interest in immunology and vascular biology. 

James supports entirely new research students come up with independently. To this end, DahlmanLab students learn how to (i) generate new ideas, (ii) select the good ones, and (iii) efficiently test whether the good ideas will actually work. 

Dahlman Lab students learn how to design/characterize/administer nanoparticles, how to isolate different cell types in vivo, how to rationally design DNA to record information, Cas9 therapies, and deep sequencing. As a result, the lab is an interdisciplinary group with students that have backgrounds in medicinal chemistry, BME, bioinformatics, biochemistry, and other fields. The lab welcomes students with all types of scientific backgrounds. The lab firmly stands by students, independent of their personal beliefs, preferences, or backgrounds.

Dr. Gabe Kwong is an Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Tech School of Engineering and Emory School of Medicine. His research program is conducted at the interface of the life sciences, medicine and engineering where a central focus is understanding how to harness the sophisticated defense mechanisms of immune cells to eradicate disease and provide protective immunity. Kwong has pioneered numerous biomedical technologies and published in leading scientific journals such as Nature Biotechnology and Nature Medicine. His work has been profiled broadly including coverage in The Economist, NPR, BBC, and WGBH-2, Boston 's PBS station. Professor Kwong earned his B.S. in Bioengineering with Highest Honors from the University of California, Berkeley and his Ph.D. in Bioengineering from California Institute of Technology with Professor James R. Heath. He conducted postdoctoral studies at Massachusetts Institute of Technology with Professor Sangeeta N. Bhatia. For his work, Dr. Kwong has been awarded the NIH Ruth L. Kirschstein National Research Service Award, named a "Future Leader in Cancer Research and Translational Medicine" by the Massachusetts General Hospital, and awarded the Burroughs Wellcome Fund Career Award at the Scientific Interface, a distinction given to the 10 most innovative bioengineers in the nation. Dr. Kwong holds seven issued or pending patents in cancer nanotechnology.

Michelle C. LaPlaca, Ph.D. is an Associate Professor in the Department of Biomedical Engineering, a joint department between Georgia Tech and Emory University. Dr. LaPlaca earned her undergraduate degree in Biomedical Engineering from The Catholic University of America, Washington, DC, in 1991 and her M.S.E. (1992) and Ph.D. (1996) in Bioengineering from the University of Pennsylvania, Philadelphia, PA, in the area of neuronal injury biomechanics. Following post-doctoral training in Neurosurgery at the University of Pennsylvania’s Head Injury Center from 1996-98, she joined the faculty at Georgia Tech. Dr. LaPlaca’s research interests are in neurotrauma, specifically: traumatic brain injury, injury biomechanics, cell culture modeling of traumatic injury, neural tissue engineering, and cognitive impairment associated with brain injury and aging. Her research is funded by NIH, NSF, and the Coulter Foundation.

Dr. Keilholz has been working in preclinical imaging for more than twenty years, with the goal of using animal models to improve the analysis of human MRI imaging. Her research uses multimodal approaches to extract information about neural dynamics from functional neuroimaging studies.

Felipe trained as a biomedical engineer in his native Colombia before obtaining a PhD from the Biomedical Engineering department of Duke University. At Duke, working in the laboratory of Ashutosh Chilkoti, he focused on the engineering of genetically-encoded, self-assembling protein polymers. An important outcome of this PhD work was the elucidation of sequence rules to program the phase separation behavior of intrinsically disordered proteins (IDPs). Motivated by a newly acquired ability to engineer the phase behavior of IDPs, for his postdoctoral work he turned to their poorly-understood biology. To pursue skin as an outstanding biological system, Felipe joined the group of Elaine Fuchs at Rockefeller University. Felipe’s postdoctoral research led to the discovery that liquid-liquid phase separation drives the process of skin barrier formation. In 2020, he established the Quiroz Lab in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, where he is currently an Assistant Professor. Felipe is the recipient of multiple research awards, including a Career Award at the Scientific Interface from the Burroughs Wellcome Fund and the NIH Director’s New Innovator Award.

Melissa Lambeth Kemp received her B.S. in Nuclear Engineering from MIT and her Ph.D. in Bioengineering from University of Washington. Dr. Kemp joined the faculty at Georgia Tech in 2006 after completing postdoctoral training at MIT. Her expertise is in computational modeling of metabolism and signal transduction, as well as developing statistical modeling tools to examine network relationships in high-dimension datasets. One major aspect of her research program linking ROS – the byproducts of aerobic metabolism – to the fundamental way that cells interpret instructions from their environment, their neighbors, and their own genetic blueprint. Specific applications of her diverse work include systems modeling of transient phosphatase oxidation of kinase cascades, patient-specific differences in cytotoxicity to redox-cycled chemotherapeutics and radiation, and the coordination of oxidative metabolism with epithelial-to-mesenchymal transition. Her research program also includes a component of developing high-throughput screening methods for assaying cue-signal-response relationships in cells and analytical tools for single cell gene expression. 

Dr. Kemp currently serves as the Research Director of the multi-site NSF Engineering Research Center “Cell Manufacturing Technologies”. In her former role as Associate Director of the NSF Science and Technology Center “Emergent Behavior of Integrated Cellular Systems”, she spearheaded the multi-site center’s computational activities by developing agent-based models of context-dependent cellular decisions to generate new hypotheses of intercellular communication in pluripotent stem cell differentiation and emergent patterning; this work continues currently in quantifying organizational principles and spatial relationships in iPSC-derived tissues from multi-omics data. Dr. Kemp’s career honors include a Whitaker Graduate Fellowship, Merck/CSBi postdoctoral fellowship, Georgia Cancer Coalition Distinguished Scholar, NIH New Innovator Award, and the CSB2 Prize for Innovative Measurement Methods from the Council for Systems Biology in Boston.